Summary
- RSV activity is rising rapidly in Pennsylvania, especially among children under age five and adults aged 65 and older.
- RSV is a leading cause of severe respiratory illness, responsible for 60,000-120,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the US.
- RSV vaccines (which are not annual) are recommended for pregnant people (32-36 weeks gestation), adults 60-74 years with certain health risks, and for everyone 75 and older.
- RSV vaccines demonstrate moderate to high efficacy in reducing morbidity and mortality especially in older adults.
- The Centers for Disease Control and Prevention (CDC) recommends all babies be protected from severe RSV by vaccinating pregnant individuals at 32-36 weeks gestational age or administering a long-acting monoclonal antibody to infants aged < 8 months entering their first RSV season and for those aged 8–19 months at increased risk for severe RSV infection.
Recommendations:
Providers should encourage RSV vaccination to their patients who are eligible to receive them. Despite these vaccines and long-acting monoclonal antibodies reducing the risk of severe RSV-related disease, many people in high-risk groups have not yet been vaccinated. CDC has created communication tools for providers to utilize to aid in increasing vaccine coverage among their patients. These resources can be found at: Resources to Prepare for Flu, COVID-19, and RSV | Respiratory Illnesses | CDC.
Widespread adoption of RSV immunizations could significantly reduce hospitalizations and deaths, especially in high-risk populations.
Take action now to protect Pennsylvania’s most vulnerable residents.
Questions:
Please contact DOH at 1-877-PA-HEALTH (1-877-724-3258) or your local health department.
For More Information
- GET THE FACTS!
- RSV Vaccines | RSV | CDC.
- RSV Vaccine Guidance for Older Adults.
- Respiratory Vaccines | Department of Health | Commonwealth of Pennsylvania.
- Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years.
- Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus.
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children.